All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What results have you seen with mosunetuzumab in patients with high-risk FL?
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Elizabeth Budde, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What results have you seen with mosunetuzumab in patients with high-risk follicular lymphoma (FL)?
What results have you seen with mosunetuzumab in patients with high-risk FL?
Budde discusses the pivotal results of a phase II trial that investigated mosunetuzumab in relapsed/refractory (R/R) FL patients, with at least 2 prior lines of therapy. She outlines the encouraging overall response rates, complete response rates, and duration of response. Finally, she summarizes that mosunetuzumab is a well tolerable treatment, with no treatment mortalities.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox